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Everolimus in Combination with Pemetrexed in Patients
with Advanced Non-small Cell Lung Cancer Previously
Treated with Chemotherapy
A Phase I Study Using a Novel, Adaptive Bayesian
Dose-Escalation Model
Johan Vansteenkiste, MD,* Benjamin Solomon, MBBS, PhD,† Michael Boyer, MBBS, PhD,‡
Ju¨rgen Wolf, MD,§ Neil Miller, MSc, Lilla Di Scala, PhD, Ilona Pylvaenaeinen, PhD,
Katarina Petrovic, MSc, Sasa Dimitrijevic, PhD, Beatrijs Anrys, RN,* and Eckart Laack, MD¶
Introduction: Pemetrexed is an established second-line therapy for
non-small cell lung cancer (NSCLC). Everolimus has previously been
shown to have some clinical activity when used as a single agent in
NSCLC. The aim of this phase I study was to evaluate the safety and
feasibility of combining pemetrexed with everolimus in patients with
NSCLC who had disease progression after one previous treatment.
Methods: Patients with stage IIIb/IV NSCLC and one previous
chemotherapy regimen were enrolled. A Bayesian dose-escalation
model was used to determine the feasible doses of daily or weekly
everolimus combined with pemetrexed (500 mg/m2 q3w). The
primary end point was rate of cycle 1 dose-limiting toxicities
(DLTs). Secondary end points included safety, relative dose inten-
sity of pemetrexed, pharmacokinetics, and tumor response.
Results: Twenty-four patients received daily everolimus (2.5, 5, 7.5,
or 10 mg) and 19 received weekly everolimus (30 or 50 mg) with
pemetrexed. Cycle 1 DLTs in the daily regimen included febrile
neutropenia, neutropenia, rash/pruritus, and thrombocytopenia; in
the weekly regimen, DLTs included neutropenia and stomatitis. The
most frequent grade 3/4 adverse events were neutropenia, dyspnea,
and thrombocytopenia. Three partial responses were observed with
everolimus 5 mg/d and two with 50 mg/wk. Pharmacokinetics did
not suggest an influence of everolimus on pemetrexed parameters;
pemetrexed resulted in a minor decrease in everolimus exposure
with both daily and weekly regimens.
Conclusions: Everolimus 5 mg/d or 50 mg/wk with the standard
regimen of pemetrexed are feasible dosages in patients with stage
IIIb/IV NSCLC.
Key Words: Everolimus, Non-small cell lung cancer, Pemetrexed,
Phase I, Adaptive Bayesian dose-escalation model.
(J Thorac Oncol. 2011;6: 2120–2129)
Current first-line standard of care for patients with ad-vanced non-small cell lung cancer (NSCLC) is platinum-
based chemotherapy.1 Adding targeted therapies such as
bevacizumab or cetuximab to platinum-based chemotherapy
has improved overall survival.2–4 However, many patients
relapse after the initial response to first-line therapy, and
second-line treatment options (i.e., docetaxel, pemetrexed, or
erlotinib) offer only modest survival benefit.5,6 No second-
line combination of cytotoxic drugs has yielded further sur-
vival benefit in large randomized clinical trials. Therefore,
combined administration of chemotherapy and targeted ther-
apies is an area deserving further exploration in patients with
progressing disease after previous treatment for NSCLC.
Activation of the phosphoinositide 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway regulates
protein synthesis and stimulates cell growth, proliferation, and
angiogenesis.7 The activated pathway is detected frequently in
NSCLC tumor samples and has been shown to promote the
survival of NSCLC cells.8,9 Everolimus, an oral inhibitor of
mTOR, has demonstrated antitumor activity in preclinical
NSCLC models10 and resulted in objective tumor responses in
patients with NSCLC when used as monotherapy and in com-
bination with erlotinib.11–13 Pemetrexed, a folate antimetabolite,
exerts its anticancer action primarily by inhibiting enzymes used
in purine and pyrimidine synthesis, such as thymidylate syn-
thase.14,15 The combination of everolimus plus pemetrexed has
demonstrated enhanced antitumor activity in a xenograft model
of NSCLC compared with pemetrexed monotherapy.16 This
phase I study investigated the feasibility of combining daily and
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weekly dosing schedules of everolimus with pemetrexed in
patients with advanced NSCLC previously treated with a single
chemotherapy regimen.
METHODS
Patients
Adults with histologically or cytologically confirmed
diagnosis of stage IIIb/IV NSCLC and World Health Orga-
nization performance status 1 were enrolled. Patients had
one previous chemotherapy regimen for advanced NSCLC,
and adequate bone marrow, liver, and renal function. Patients
were excluded if they received previous treatment with any
mTOR inhibitor; required chronic steroid or other immuno-
suppressant therapy; had uncontrolled, symptomatic brain or
leptomeningeal metastases; or had active respiratory, skin,
mucosal, renal, neurologic, or ocular disorders of grade 1.
Antineoplastic therapy (other than study medication), systemic
corticosteroids 2 weeks in duration, or strong inhibitors or
inducers of cytochrome P-450 enzymes were not permitted
during the study. Administration of bisphosphonates, analgesics,
hematopoietic growth factors for cytopenia (except during cycle
1), and prophylactic antiemetics was allowed.
All patients provided written informed consent before any
study-related procedure was performed. The study was con-
ducted according to the Declaration of Helsinki, with approval
by the institutional review board of the participating institutions.
Study Design and Treatment
This was an open-label, multicenter, dose-escalation,
phase I study. The design of the sequential dose-escalation
scheme was based on evaluation of toxicity and application of
a novel, adaptive Bayesian model. Up to 3 daily (2.5, 5, and
10 mg PO; days 1–21) and 3 weekly (20, 30, and 50 mg PO;
days 1, 8, and 15) dose levels of everolimus were planned to
be evaluated in combination with pemetrexed 500 mg/m2 (see
slide, Supplemental Digital Content 1, which depicts the
study design, http://links.lww.com/JTO/A162). Study treat-
ment was repeated every 21 days up to six cycles (core
treatment phase). Pemetrexed was administered intrave-
nously on day 1 of each cycle. Everolimus daily dosing began
on day 2 of cycle 1, and weekly doses were administered on
days 1 (day 2 in cycle 1), 8, and 15 of each cycle. To reduce
toxicity associated with pemetrexed, patients in the study
were pretreated with folic acid, vitamin B12, and dexameth-
asone according to local practice. Dose adjustments made for
drug-related hematologic and nonhematologic toxicities are de-
scribed in the table provided in Supplemental Digital Content 2
for this article (http://links.lww.com/JTO/A163). After the core
phase, patients could enter the extension phase with either
everolimus alone, pemetrexed alone, or the combined study
treatment until disease progression or unacceptable toxicity.
Assessments
Adverse events (AEs) were assessed according to Na-
tional Cancer Institute Common Terminology Criteria for AEs,
version 3.0. Safety assessments included physical examination,
vital signs, and laboratory evaluations at baseline and on day 1
of each cycle (with hematologic laboratory values evaluated
weekly) during the 6-cycle core phase and every 3 to 4 weeks
thereafter. Dose-limiting toxicity (DLT) was defined as a treat-
ment-related AE or laboratory abnormality that occurred during
the core phase of the study and met one of the following criteria:
febrile neutropenia, grade 4 thrombocytopenia, grade 3 pneu-
monitis, or grade 4 nonhematologic event despite appropriate
prophylactic treatment (except hyperlipidemia and hyperglyce-
mia). In addition, the following events were DLTs if 7 days
were needed to resolve to grade 1 or recurring in the same
cycle: grade 3/4 nonfebrile neutropenia, grade 3 thrombocyto-
penia, grade 3 nonhematologic event (except hyperlipidemia,
hyperglycemia, and pneumonitis), or grade 2 pneumonitis or
other intolerable grade 2 event despite appropriate prophylactic
treatment. A critical DLT was defined as any DLT occur-
ring during the first 21 days (cycle 1) of treatment. Com-
puted tomography scans for tumor measurements were
performed at baseline, every 6 weeks during the core
phase, and 6 to 8 weeks thereafter. Tumor responses were
analyzed according to RECIST (version 1.0).17
Serial blood samples for evaluation of the pharmaco-
kinetic (PK) profile of everolimus were collected on day 8 of
cycle 1 and day 2 of cycle 2, before and 0.5, 1, 2, 4, and 24
hours (and 168 hours for weekly schedule only) after dosing.
Additional predose samples were collected on day 1 of every
cycle thereafter. To assess pemetrexed PK, additional blood
samples were collected at 10, 15, and 30 minutes, and 1, 2, 4,
and 24 hours on day 1 of cycle 1 and cycle 2. Whole blood
concentrations of everolimus and plasma concentrations of
pemetrexed were determined by liquid chromatography-mass
spectroscopy methods, with a lower limit of quantitation of
0.3 ng/ml and 10 ng/ml, respectively.
PK parameters for everolimus and pemetrexed were
derived by standard noncompartmental analysis using Win-
Nonlin, version 5 (Pharsight, Sunnyvale, CA). PK parameters
of everolimus were compared on day 8 of cycle 1 and day 1
of cycle 2 to examine any potential impact of pemetrexed on
everolimus PK; comparing pemetrexed parameters on day 1
of cycles 1 and 2 would enable detection of potential impact
of everolimus on pemetrexed PK, if any.
End Points and Statistical Analysis
The primary end point was the rate of DLTs at the end of
cycle 1. A novel, adaptive Bayesian time-to-DLT model was
used to guide dose escalation and determine the feasible dose
levels of everolimus combined with pemetrexed.18,19 The Bayes-
ian model assumes that the time to DLT follows a Weibull
distribution from which the probability of a DLT in cycle 1 was
derived. Input into the model is time-to-DLT or time-to-censor-
ing (if a patient does not experience a DLT). Only time to first
DLT is taken into account. Historical data for single-agent
everolimus DLT rates were used to estimate the previous as-
sumption on the toxicity rate. Dose-escalation decision making
was made based on the distribution of the probability of the
critical DLT rate falling within prespecified intervals: 0% to
20%, underdosing interval; 20% to 35%, targeted toxicity inter-
val; 35% to 60%, excessive toxicity interval; and 60% to 100%,
unacceptable toxicity interval. A dose level of everolimus was
defined as feasible if it maximized the probability of the critical
DLT rate falling within the targeted toxicity interval and corre-
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sponded to a 5% chance of the rate being within the unac-
ceptable toxicity interval and a 25% chance of being within
the excessive and unacceptable toxicity intervals combined.
Secondary end points of the study included safety, relative
dose intensity (RDI) of pemetrexed, potential PK drug-drug
interactions, and efficacy. The RDI of pemetrexed was predicted
by Bayesian mixed-effects model20 and was expected to not fall
below 80% to maintain the efficacy of the standard chemother-
apy. The PK parameters, including the maximum observed
concentration (Cmax), time to reach maximum concentration
(Tmax), and area under the concentration-time curve during a
dosing interval, were estimated using standard noncompartmen-
tal methods. Best overall response rates and corresponding 95%
confidence intervals were estimated using Clopper-Pearson
method. Descriptive statistics were used to summarize AEs and
patient baseline characteristics. All patients who received 1
dose of either study drug were included in the efficacy analysis;
inclusion in the safety analysis also required patients to have1
postbaseline safety assessment. The dose-determining popula-
tion included all patients from the safety population who re-
ceived both study drugs for at least the first cycle or who had a
DLT at any time in the core phase and was used to run the
time-to-DLT model. The PK analyses were performed on the
safety population that had 1 evaluable blood sample.
It was anticipated via simulations that explored differ-
ent underlying toxicity scenarios that approximately 30 pa-
tients would be sufficient to complete dose escalation within
each regimen (daily or weekly everolimus) and to ensure the
desired level of confidence in estimating the critical DLT rate
and the RDI of pemetrexed.
RESULTS
Patients and Treatment
The results presented here are based primarily on data
from the core treatment phase unless stated otherwise. A total
of 43 patients were enrolled in the study from December 2006
to October 2008, at 5 participating centers. Twenty-four
patients were centrally allocated to receive one of four daily
dose levels of everolimus plus pemetrexed. An unplanned
dose level, 7.5 mg/d, was initiated because of excessive
toxicity observed at the 10 mg/d dose level. Nineteen patients
were allocated to receive one of two weekly dose levels of
everolimus plus pemetrexed. The 20 mg/wk dose level was
not investigated, because the weekly starting dose level of 30
mg/wk proved to have an excellent tolerability profile, such
that the model never suggested down escalating.
Patient characteristics are listed in Table 1. Although
previous treatment with pemetrexed was not specifically
excluded in this study, at the time of the writing of the initial
protocol, pemetrexed was not approved for use in the first-
line setting, and no patients received pemetrexed before
enrollment. All patients were included in the safety and
efficacy analyses; two patients in the weekly dosing arm were
excluded from the dose-determining population because they
did not receive sufficient everolimus treatment during cycle
1. The median RDI of pemetrexed ranged from 88% to 100%
of the planned dose intensity. The median duration of treat-
ment was 5.1 to 11.9 weeks for everolimus and 2 to 4 cycles
for pemetrexed (Table 2). Fewer than 30% of patients in both
regimens received the targeted six cycles of combined study
treatment (Table 2). The most common reason for treatment
discontinuation from the six-cycle core phase was disease
progression. Discontinuation from the core phase because of
an AE or laboratory abnormality occurred in six patients who
received daily everolimus and in three patients who received
weekly everolimus (Table 2).
Dose-Limiting Toxicities
All critical DLTs (occurring during study cycle 1) and
noncritical DLTs (occurring during cycles 2–6) are reported in
Table 3. For the daily dosing schedule (Figure 1), once the first
TABLE 1. Patient Characteristics
Characteristic
Dose Cohort
Daily Everolimus (mg)/Pemetrexed (mg/m2)
Weekly Everolimus (mg)/
Pemetrexed (mg/m2)
2.5/500,
n  5
5/500,
n  12
7.5/500,
n  4
10/500,
n  3
Total,
n  24
30/500,
n  6
50/50,
n  13
Total,
n  19
Median age, range (yr) 58 (37–68) 63.5 (52–74) 53.0 (45–57) 63.0 (60–66) 59.5 (37–74) 65.5 (43–74) 59.0 (36–72) 60.0 (36–74)
Sex, n
Female 3 3 2 2 10 2 6 8
Male 2 9 2 1 14 4 7 11
WHO PS (0:1), n 2:3 4:8 1:3 0:3 7:17 0:6 8:5 8:11
Smoking status, n
Never 2 0 0 1 3 1 2 3
Ever 3 12 4 2 21 5 11 16
Current 1 2 1 0 4 0 2 2
Histology/cytology, n
Adenocarcinoma 3 10 3 3 19 3 12 15
Large-cell carcinoma 2 1 1 0 4 1 0 1
Squamous cell carcinoma 0 1 0 0 1 2 1 3
WHO PS, World Health Organization performance status.
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enrolled patient receiving everolimus 5 mg/d experienced a
critical DLT (grade 3 rash), recruitment was initiated for the 2.5
mg/d dose. After five patients were successfully treated at 2.5
mg/d, the dose was again escalated to 5 mg/d. Although the
incidence of the noncritical DLT neutropenia (33%) was rela-
tively high in the 5 mg/d cohort, the dose was escalated to 10
mg/d after 11 additional patients in the 5 mg/d cohort had been
treated. Three patients were treated at 10 mg/d, two of whom
experienced critical DLTs (febrile neutropenia and neutropenia)
and other severe toxicities that prevented further enrollment at
this level as determined by the study investigators. Subse-
quently, a new 7.5 mg/d dose was introduced, and four patients
were treated at this level. Two patients receiving 7.5 mg/d
experienced critical DLTs (febrile neutropenia [n  1]; grade 3
pruritus, rash, and thrombocytopenia [n  1]), thereby prevent-
ing treatment of additional patients at this level.
TABLE 2. Patient Disposition and Treatment Exposure
Dose Cohort
Daily Everolimus (mg)/Pemetrexed (mg/m2)
Weekly Everolimus (mg)/
Pemetrexed (mg/m2)
2.5/500, n  5 5/500, n  12 7.5/500, n  4 10/500, n  3 30/500, n  6 50/500, n  13
Completed six cycles, n 1 5 1 0 2 3
Entered extension phasea, n 1 6 1 0 2 4
Discontinued, n 4 7 3 3 4 10
AEs 0 2 2 0 0 2
Abnormal laboratory values 2 0 0 0 0 1
Administrative problems 0 0 0 0 0 1
Death 0 0 0 0 0 1
Disease progression 2 5 1 3 4 4
New cancer therapy 0 0 0 0 0 1
Median duration of everolimus
exposure, wk (range)
7.9 (5.9–18.3) 7.9 (2.7–22.9) 5.1 (1.0–18.6) 11.9 (5.9–12.0) 11.8 (5.7–19.0) 11.7 (1.0–19.9)
Median number of pemetrexed
cycles (range)
3 (2–6) 3 (1–6) 2 (1–6) 4 (2–4) 4 (2–6) 4 (1–6)
Median RDI of pemetrexedb (range) 0.98 (0.75–1.00) 0.99 (0.77–1.02) 0.99 (0.96–1.00) 0.88 (0.74–0.99) 1.00 (0.86–1.01) 1.00 (0.65–1.02)
a Patients could enter the extension phase after completing six cycles or discontinuing from the first phase of the study (shown in Supplemental Digital Content 1).
b Relative dose intensity calculated from available cycles is the dose intensity divided by the planned dose intensity.
TABLE 3. Dose-Limiting Toxicities
Dose Cohort
Daily Everolimus (mg)/Pemetrexed (mg/m2)
Weekly Everolimus (mg)/
Pemetrexed (mg/m2)
2.5/500, n  5 5/500, n  12 7.5/500, n  4 10/500, n  3 30/500, n  6 50/500, n  13
Critical DLTs, cycle 1, n (patients) 0 2 2 2 0 2
Critical DLTs, cycle 1, n (events)
Febrile neutropenia 0 0 1 1 0 0
Neutropenia 0 0 0 1 0 1
Rash/pruritus 0 1 2 0 0 0
Stomatitis 0 0 0 0 0 1
Thrombocytopenia 0 1 1 0 0 0
Noncritical DLTs, cycles 2–6, n (patients) 1 4 1 0 0 4
Noncritical DLTs, cycles 2–6, n (events)
Anemia 0 0 0 0 0 1
Catheter-related infection 0 0 0 0 0 1
Fatigue 0 1 0 0 0 0
Mobility decreased 0 1 0 0 0 0
Neutropenia 1 4 0 0 0 1
Pneumonitis 0 0 0 0 0 1
Stomatitis 0 0 0 0 0 1
Thrombocytopenia 0 1 1 0 0 0
DLTs, dose-limiting toxicities.
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For the weekly dosing schedule (Figure 2), once six
patients receiving 30 mg/wk had completed cycle 1 with no
DLTs, the dose was escalated to 50 mg/wk. Thirteen patients
were treated at 50 mg/wk until recruitment ceased.
Conduct of the Study
The decisions concerning dosing were taken at prespeci-
fied time points (to allow prompt reaction after a toxicity event
such as a critical DLT) and took into account model-based
information and clinical assessment of risk-benefit for patients
(primarily based on AE severity). At each decision time point,
the most updated probabilities based on the time-to-event model
(such as the probability distribution for critical DLT rate at the
end of cycle 1) were determined for each dose cohort and
discussed with investigators. The decision-making time points in
relation to the staggered study recruitment at the various dose
levels are shown in Figures 1 (daily) and 2 (weekly). At the final
decision time point (no. 7), in the daily schedule only, a discrep-
ancy occurred between clinical assessment (declaration of 5
mg/d as the feasible dose) and model-based evaluation (7.5 mg/d
as the feasible dose). Strictly applying the predefined criteria of
feasibility from the time-to-DLT model, everolimus 7.5 mg/d
would have been considered a feasible dose based on the
primary end point alone (Table 4). At all other decision points in
the daily schedule and at all points in the weekly schedule,
model-based recommendations and clinical recommendations
coincided. The decision to include the additional 7.5 mg/d dose
was only made at decision time point no. 6 (see Figure 1). Study
recruitment decisions would likely have been different had this
dose level been included from the start of the study (i.e.,
treatment at the 10 mg/d dose could have been avoided and the
feasible daily dose could have been identified sooner).
Adverse Events
All patients experienced AEs during the study. The
most common AEs reported were rash (70.8%), neutropenia
(66.7%), and fatigue (66.7%) in the everolimus daily regimen
and neutropenia (68.4%), rash (57.9%), and anorexia (52.6%)
in the everolimus weekly regimen. More than 95% of patients
experienced at least one clinically notable AE (AE for which
there is a specific clinical interest in connection with everoli-
mus treatment). Neutropenia and rash were the most common
clinically notable AEs experienced by patients. Pneumonitis
was reported in two patients during the study, one in each of
the everolimus 10 mg/d and 50 mg/wk cohorts.
Seven patients in the daily treatment regimen and four
patients in the weekly treatment regimen discontinued treatment
because of AEs; among those, five had AEs suspected to be
related to study treatment: grade 3 neutropenia, grade 3 decreased
mobility, grade 3 fatigue, grade 3 pruritus, and grade 2 pneumonitis.
Grade 3 or 4 AEs occurred in 88% of patients in the
daily regimen and 74% in the weekly regimen (Table 5). The
most common grade 3 or 4 AEs were neutropenia (62.5%),
thrombocytopenia (20.8%), leukopenia (16.7%), and dyspnea
(16.7%) in the daily regimen and neutropenia (57.9%), dys-
pnea (21.1%), thrombocytopenia (15.8%), leukopenia
(15.8%), anemia (15.8%), and stomatitis (15.8%) in the
weekly regimen. Serious AEs were reported in 42% of
patients overall; there was no trend or clustering of serious
AEs in any system organ class. Six patients died during the
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study because of NSCLC: one in each of the 5 mg/d and 10
mg/d groups and two patients in each of the weekly groups.
Tumor Response
Efficacy was assessed based on all available data from
both the core and the extension phases. Partial response (PR),
confirmed after a minimum of 4 weeks since it was initially
declared using RECIST, was the best overall response for
three patients in the everolimus 5 mg/d group (25%) and for
two patients in the everolimus 50 mg/wk group (15%).
Disease control rate (PR and stable disease) was 42% of patients
overall (see Table, Supplemental Digital Content 3, showing
best overall response, http://links.lww.com/JTO/A164). Of the
patients who received daily or weekly everolimus, 52% and
43%, respectively, overall had a decrease in the sum of longest
diameter compared with baseline (see Figure, Supplemental Digital
Content 4, for waterfall plot, http://links.lww.com/JTO/A164).
Pharmacokinetics
Increasing doses of everolimus did not have any sig-
nificant influence on pemetrexed PK parameters (Table 6). In
addition, pemetrexed PK parameters were comparable with
values reported in the literature where pemetrexed was ad-
ministered either alone or in combination with other
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FIGURE 2. Recruitment graph with DLTs for weekly dosing schedule (from first patient, first visit to end of treatment
core).**Two patients (one in the 30 mg/wk cohort and one in the 50 mg/wk cohort) were excluded from the decision-making
analysis set, because they did not receive sufficient everolimus dosing in cycle 1 to be eligible for inclusion. DLT, dose-limiting
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TABLE 4. Probabilities of Critical Dose-Limiting Toxicity Rate For Cycle 1 at End of the Dose Escalation
Dose Cohorta
Daily Everolimus (mg)/
Pemetrexed (mg/m2)
Weekly Everolimus (mg)/
Pemetrexed (mg/m2)
2.5/500,
n  5 (%)
5/500,
n  12 (%)
7.5/500,
n  4 (%)
10/500,
n  3 (%)
30/500,
n  5 (%)
50/500,
n  12 (%)
(0%, 20%), Underdosing interval 97 72 32 17 100 92
(20%, 35%), Targeted toxicity interval 3 28 59 51 0 8
(35%, 60%), Excessive toxicity interval 0 0 9 29 0 0
(60%, 100%), Unacceptable toxicity 0 0 0 2 0 0
Excessive  unacceptable toxicity 0 0 9 31 0 0
a Determined in the dose-determining population.
Time-to-DLT/censoring: Daily: 56*, 64, 85, 129, 43 (2.5 mg); 5*, 26*, 15*, 65*, 93*, 51*, 22, 129, 130, 127, 43, 44 (5 mg); 10*, 12*, 31, 23 (7.5 mg); 8*, 8*, 85 (10 mg);
Weekly: 127, 50, 84, 85, 127 (30 mg); 43*, 7*, 43*, 8*, 43*, 23, 128, 84, 127, 85, 43, 127 (50 mg), where asterisk (*) indicate time to DLT and all other values are time to censoring.
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drugs.21,22 Pemetrexed administration seemed to result in a
decrease in Cmax and overall systemic exposure (area under
the curve) of everolimus across all dose levels of everolimus
(daily and weekly).
DISCUSSION
This phase I study was initiated to establish the recom-
mended daily or weekly dose of everolimus in combination
with pemetrexed in the second-line treatment of patients with
NSCLC. Everolimus in combination with pemetrexed gener-
ally was well tolerated, and everolimus could be administered
at doses within the range of the single-agent standard doses
with an acceptable safety profile.
This study used an adaptive Bayesian method18,19,23 to
determine the feasible dose levels of everolimus in combina-
tion with pemetrexed in patients with pretreated NSCLC.
This novel design improves on the traditional phase I “33”
design in that it provides a flexible dose escalation scheme
using DLT data on all dose levels at each decision point,
leading to more informed decision making. Bayesian phase I
designs similar to this have been used extensively and their
advantages with respect to conventional algorithms are
known.24 The adaptive nature of the time-to-event model also
allows the DLT rate to be evaluated at any time during the
study, ensuring a prompt reaction after a toxicity event, and
allows flexibility in terms of the number of patients enrolled
at each dose level, thus avoiding the need to predefine the size
of a cohort. The dose of 7.5 mg/d was introduced half way
through the study. Including the 7.5 mg/d dose from the
beginning of the study might have avoided exploring the 10
mg/d dose and also triggered an earlier escalation to the
(higher) 7.5 mg/d dose, instead of continued enrollment at 5
mg/d (also because of reluctance to double the dose before
gaining a sufficient level of confidence in the safety of the 5
mg/d dose). Choosing an unplanned dose level of 7.5mg/d
caused a delay in the study that could have been avoided by
specifying only the dose range at the outset of the study and
not the specific doses investigated, because the model itself
allowed straightforward inclusion of additional dose levels
within that range.
Based on the time-to-DLT model, everolimus 7.5 mg/d
and 50 mg/wk were considered feasible doses. However, the
clinical opinion of the investigators and the cycle-1 DLT data
indicated that the toxicities reported at 7.5 mg/d were unac-
ceptable. Feasibility results from the time-to-DLT model
were heavily influenced by the long censoring times (duration
of treatment without DLT) observed with the 5 and 7.5 mg/d
doses, which resulted in an underestimation of the chance of
excessive/unacceptable toxicity at the highest daily doses (see
footnote to Table 4). This can explain the discrepancy be-
tween model estimates and the cycle-1 toxicity data actually
observed. The 50 mg/wk dose indicates a very high chance of
underdosing (Table 4) according to the model, although there
was reluctance to escalate the dose of everolimus to any
further (unplanned) weekly dose level based on the toxicities
reported. Thus, everolimus 5 mg/d or 50 mg/wk with the
standard regimen of pemetrexed are the recommended doses
for further clinical study. Adaptive Bayesian models are
attractive for their flexibility and ability to quantify risks of
overdosing. However, the model chosen for the study may
have been inadequate. An alternative Bayesian model cen-
tered solely around cycle-1 critical DLTs18 may have been
more appropriate and may have been better aligned with
actually observed data and with clinical judgement. More
methodological research is needed in the field of modeling
time to DLT in combination with cycle-1 DLT data.
The combination of everolimus and pemetrexed gener-
ally was well tolerated, but the frequency and severity of AEs
in this study were higher than those in clinical studies of
single-agent everolimus or single-agent pemetrexed in
NSCLC,5,13 which may be due to the overlapping toxicities of
these two agents. In particular, a higher incidence of grade 3
or 4 neutropenia was noted among patients receiving the
combination of pemetrexed and everolimus compared with
the incidence reported for pemetrexed alone,25 although only
one episode of febrile neutropenia was reported. Pneumonitis,
TABLE 5. Most Common Grade 3 and 4 AEsa
AE, n (patients)
Dose Cohort
Daily Everolimus (mg)/
Pemetrexed (mg/m2)
Weekly Everolimus (mg)/
Pemetrexed (mg/m2)
2.5/500, n  5 5/500, n  12 7.5/500, n  4 10/500, n  3 30/500, n  6 50/500, n  13
Hematologic
Anemia 0 1 0 1 0 3
Leukopenia 0 3 0 1 0 3
Neutropenia 2 7 4 2 4 7
Thrombocytopenia 0 3 2 0 1 2
Nonhematologic
Dyspnea 1 1 2 0 1 3
Fatigue 0 1 0 1 0 2
Pleural effusion 1 0 0 0 1 1
Rash/pruritus 0 1 1 1 0 1
Stomatitis 0 0 0 0 0 3
a In at least 10% of patients across all dose levels in a dosing regimen.
Vansteenkiste et al. Journal of Thoracic Oncology • Volume 6, Number 12, December 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer2126
TA
B
LE
6.
Ev
er
ol
im
us
an
d
Pe
m
et
re
xe
d
PK
Pa
ra
m
et
er
s
P
ar
am
et
er
a
2.
5
m
g/
d
5
m
g/
d
7.
5
m
g/
d
10
m
g/
d
30
m
g/
w
k
50
m
g/
w
k
E
ve
ro
lim
us

P
em
et
re
xe
d
E
ve
ro
lim
us

P
em
et
re
xe
d
E
ve
ro
lim
us

P
em
et
re
xe
d
E
ve
ro
lim
us

P
em
et
re
xe
d
E
ve
ro
lim
us

P
em
et
re
xe
d
E
ve
ro
lim
us

P
em
et
re
xe
d
E
ve
ro
lim
us
A
lo
ne
(n

6)
W
it
h
P
em
et
re
xe
d
(n

4–
5)
E
ve
ro
lim
us
A
lo
ne
(n

8–
10
)
W
it
h
P
em
et
re
xe
d
(n

6–
9)
E
ve
ro
lim
us
A
lo
ne
(n

1)
W
it
h
P
em
et
re
xe
d
(n

1)
E
ve
ro
lim
us
A
lo
ne
(n

1)
W
it
h
P
em
et
re
xe
d
(n

1)
E
ve
ro
lim
us
A
lo
ne
(n

4–
5)
W
it
h
P
em
et
re
xe
d
(n

3–
4)
E
ve
ro
lim
us
A
lo
ne
(n

7–
9)
W
it
h
P
em
et
re
xe
d
(n

7–
10
)
E
ve
ro
li
m
us
(n
g/
m
l)
6.
15

2.
97
3.
51

2.
72
9.
89

5.
15
13
.4
9

8.
19
12
.1
10
.9
9.
46
10
.6
0.
95

0.
35
0.
8

0.
47
6
2.
28

2.
12
1.
97

2.
30
C
m
ax (n
g/
m
l)
33
.0

5.
57
14
.1

9.
17
46
.3

26
.4
31
.0

18
.0
10
9
36
.8
11
5
58
.8
23
2.
2

48
.1
13
6.
9

57
.3
25
0.
6

89
.8
14
4.
6

90
.1
T
m
ax
(h
)
1.
0
(0
.5
–2
.0
)
1.
75
(0
.4
–2
.0
)
1
(0
.5
–2
3.
8)
1
(0
.5
–4
.0
)
0.
5
0.
42
0.
5
1.
02
1.
0
(0
.5
–1
.0
)
0.
5
(0
.5
–2
.0
)
1.
0
(0
.5
–1
.0
)
1.
03
(0
.5
–2
.0
)
A
U
C ng

h/
m
l)
30
6.
4

11
3
13
8.
6

83
.6
38
4.
4

20
3.
0
30
7.
9

23
0.
5
61
3.
7
40
8.
9
64
2.
1
51
2.
4
31
70
.4

41
6.
1
24
27
.2

51
7.
1
77
69
.4

53
90
48
93
.6

48
56
C
L
/F
(L
/h
)
10
.5

4.
31
37
.8

40
.6
14
.2

5.
87
29
.7

36
.3
12
.2
18
.3
15
.7
19
.5
9.
55

1.
14
12
.7

2.
65
9.
26

5.
22
25
.1

24
.5
P
em
et
re
xe
d
A
lo
ne
(n

5)
W
it
h
E
ve
ro
lim
us
(n

3–
5)
P
em
et
re
xe
d
A
lo
ne
(n

9–
10
)
W
it
h
E
ve
ro
lim
us
(n

8–
10
)
P
em
et
re
xe
d
A
lo
ne
(n

1)
W
it
h
E
ve
ro
lim
us
(n

1)
P
em
et
re
xe
d
A
lo
ne
(n

1)
W
it
h
E
ve
ro
lim
us
(n

1)
P
em
et
re
xe
d
A
lo
ne
(n

5)
W
it
h
E
ve
ro
lim
us
(n

5)
P
em
et
re
xe
d
A
lo
ne
(n

9–
10
)
W
it
h
E
ve
ro
lim
us
(n

9–
10
)
P
em
et
re
xe
d
C
m
ax (
g/
m
l)
12
1.
1

35
.4
11
0.
9

25
.9
13
8.
7

12
1.
8
11
7.
6

78
.1
86
.9
13
2
72
.5
15
3
11
2.
8

37
.9
10
9.
1

39
.6
10
0.
4

26
.2
96
.6

57
.6
T
m
ax
(h
)
0.
33
(0
.2
–0
.3
)
0.
33
(0
.3
–0
.3
)
0.
17
(0
.2
–0
.2
)
0.
18
(0
.2
–0
.3
)
0.
17
0.
17
0.
25
0.
23
0.
37
(0
.2
–0
.4
)
0.
33
(0
.2
–0
.4
)
0.
17
(0
.2
–0
.3
)
0.
18
(0
.2
–0
.5
)
A
U
C 
g

h/
m
l)
27
7.
4

91
.9
20
0.
7

23
.1
26
1.
7

53
.0
22
7.
2

87
.4
26
4.
2
21
8.
5
15
9.
8
25
4.
2
32
3.
3

84
.6
28
9.
0

38
.8
20
6.
2

45
.1
20
0.
3

10
6.
3
T
1
/2
(h
)
2.
60

0.
31
3
2.
59

0.
42
6
3.
27

0.
52
6
3.
3

0.
95
2.
17
2.
09
2.
5
2.
37
2.
76

0.
45
9
2.
80

0.
59
2
2.
86

0.
39
1
3.
35

1.
37
a
V
al
ue
s
ar
e
li
st
ed
as
m
ea
n

S
D
ex
ce
pt
fo
r
T
m
ax
,
w
hi
ch
is
li
st
ed
as
m
ed
ia
n
(r
an
ge
).
A
U
C
,
ar
ea
un
de
r
th
e
cu
rv
e
fr
om
ti
m
e
0
to
th
e
la
st
sa
m
pl
e
po
in
t;
C
L
/F
,
or
al
cl
ea
ra
nc
e;
C
m
ax
,
m
ax
im
um
co
nc
en
tr
at
io
n;
C
m
in
,
m
in
im
um
co
nc
en
tr
at
io
n;
T
m
ax
,
ti
m
e
to
C
m
ax
;
T
1
/2
,
te
rm
in
al
ha
lf
-l
if
e.
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 Combination of Everolimus Plus Pemetrexed in NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 2127
a class effect of mTOR inhibitors, was observed in 5% of the
patients (n  2), consistent with that reported in the phase III
trial of everolimus in advanced renal cell carcinoma.26 Sto-
matitis has been the main DLT in previous phase I studies of
everolimus.11 In this study, two patients in the 50 mg/wk
cohort experienced stomatitis as DLT during the core treat-
ment phase of the study. Stomatitis was reported as one of the
most common grade 3 or 4 AEs in the weekly regimen
(15.8%).
The assessment of tumor response was a secondary
objective of this study. Everolimus in combination with
pemetrexed seemed to show clinical activity in pretreated
NSCLC. Considering core and extension data, 6 patients
(14%) achieved PR, one of which was confirmed in the
extension when the patient was not treated with everolimus;
12 patients (28%) had stable disease. This response was
comparable with reported response data for everolimus-con-
taining regimens in NSCLC clinical trials.12,13 Patients with
all histologic subtypes of NSCLC were enrolled in the study,
because the differential efficacy of pemetrexed according to
histology in NSCLC27,28 was not known at the time of study
development and initiation. All the PRs observed in this study
were seen in patients with adenocarcinomas, consistent with
the known activity of pemetrexed in NSCLC patients with
nonsquamous histology.27,28 However, interpretation of the
tumor responses is limited by the small sample size in each
cohort. Further investigation of the effect of everolimus in
combination with pemetrexed in patients with pretreated
nonsquamous NSCLC is warranted. In addition, studies on
predictive markers for the efficacy of everolimus in combi-
nation with pemetrexed will be useful, because these markers
may identify patients with NSCLC who are most likely to
benefit from this combination therapy.
PK analyses did not suggest an influence of everolimus
on pemetrexed exposure; however, pemetrexed resulted in a
minor decrease in everolimus exposure with both the daily
and weekly regimens. Although this decrease appeared sig-
nificant at the 2.5 mg/d and 30 mg/wk everolimus dose levels,
few patients in each dose group and the associated variability
prevented this observation from being meaningful across all
everolimus dose levels. This drug-drug interaction cannot be
accounted for by known elimination pathways of everolimus
and pemetrexed, because everolimus is primarily metabolized
by the CYP3A4 pathway, whereas pemetrexed is eliminated
in the urine, with little to no hepatic metabolism.
This phase I study used an adaptive Bayesian dose-
escalation method to examine the feasible combination of
everolimus with pemetrexed in patients with pretreated
NSCLC. The combination of everolimus and pemetrexed was
generally well tolerated, but the frequency and severity of
AEs in this study were higher than those in clinical studies of
single-agent everolimus or single-agent pemetrexed in
NSCLC. The results indicate that everolimus 5 mg/d or 50
mg/wk with the standard regimen of pemetrexed are feasible
dosages in patients with stage IIIB/IV NSCLC.
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